TwinStrand Biosciences

TwinStrand Biosciences has pioneered Duplex Sequencing®, a proprietary error-corrected NGS technology that achieves an error rate of less than 1 in 10 million, representing a >10,000-fold improvement over standard NGS. This ultra-sensitive platform is being applied to key areas including measurable residual disease (MRD) monitoring in hematological cancers like AML and next-generation genetic toxicology assays for regulatory safety assessment. The company is transitioning its mutagenesis assay business through an acquisition by Scantox while focusing on advancing its diagnostic and research applications, positioning itself at the forefront of high-fidelity genomic analysis.

Duplex Sequencing®: An error-corrected next-generation sequencing (ecNGS) technology that independently tags and sequences both strands of individual DNA molecules, comparing results to eliminate technical errors and achieve an error rate of <1 in 10 million, enabling detection of ultra-rare genetic variants.

TwinStrand competes in the high-sensitivity sequencing space against companies offering digital PCR and standard NGS panels for MRD, and against traditional in vivo genetic toxicology assays. Its primary competitive advantage is its exceptional error rate, but it faces challenges from the entrenched market position of incumbents and potential future competition from other ecNGS approaches.